Showing results (171-180 of 181) with videos related to
Sort By:
Pageof 19
Oncotarget|February 16, 2011
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesisMichiel Smits, Jonas Nilsson, Shahryar E Mir, et al.Cancer Cell|November 13, 2007
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancerJindan Yu, Qi Cao, Rohit Mehra, et al.The Journal of Biological Chemistry|February 22, 2012
Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol esterTamas Geczy, Megan L Peach, Saïd El Kazzouli, et al.Cancer Cell|October 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.BMC Cancer|March 1, 2014
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMSRoberta Ciarapica, Elena Carcarino, Laura Adesso, et al.Bioorganic & Medicinal Chemistry|May 6, 2014
Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRPLia C Garcia, Lucia Gandolfi Donadío, Ella Mann, et al.Journal of Medicinal Chemistry|March 17, 2006
Branched diacylglycerol-lactones as potent protein kinase C ligands and alpha-secretase activatorsJeewoo Lee, Ji-Hye Kang, Kee-Chung Han, et al.Blood|December 31, 2010
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylationDamian B Yap, Justin Chu, Tobias Berg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2011
Polycomb repressor complex-2 is a novel target for mesothelioma therapyClinton D Kemp, Mahadev Rao, Sichuan Xi, et al.Cancer Research|October 27, 2012
Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancerShun X Ren, Alfred S L Cheng, Ka F To, et al.Pageof 19